Last reviewed · How we verify
OGX-011
At a glance
| Generic name | OGX-011 |
|---|---|
| Sponsor | University of British Columbia |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer (PHASE2)
- OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors (PHASE1)
- Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer (PHASE1)
- Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy (PHASE2)
- Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer (PHASE2)
- Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (PHASE3)
- Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (PHASE3)
- A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |